|
会议将同时进行
|
|
Clinical Trials Asia 概要
|
|
[
概要 |
展销前置会 |
1日目 |
2日目 |
3日目 |
Catalog(PDF) ]
|
|

第2回 亚洲治疗实验 - 印度、中国、东南亚中治疗实验的企画、设定、实施战略
2008年3月26~28日
- 印度、中国、东南亚中治疗实验设计和企画
- 伦理审查委员会过程的管理
- 印度的安全性报告和医药品安全对策实施
- 亚洲的规定动向介绍
- 亚洲的治疗实验的设计及实施上的战略及战术检讨事项:从其它事例得到的教训
- 物流问题的克服和合作者(partner)的管理,规范(compliance)的保证
|
|
FEATURED
PRESENTATIONS: |
 |
Utilizing and Integrating Data from China to Mutually
Support Global and Local Applications
James Cai, M.D., Vice President, R&D and Business
Development, AstraZeneca Pharmaceuticals, China |
 |
Country and Site Selection for Global Clinical Trials
Fidela Ll. Moreno, M.D., Executive Director, Global Development
Operations, Asia and Latin America, Amgen Inc. |
 |
Recent Regulatory Changes in India
Chandrashekhar Potkar, M.D., Director, Clinical Research,
Pfi zer Ltd. (India) |
 |
Optimizing Return on Investment
(ROI) of Multinational
and Domestic Clinical Trials in China
Min Irwin, M.D., Ph.D., Medical Director of BSP China, Bayer
HealthCare Company Ltd. |
 |
Roles and Functioning of Institutional and Independent
Ethics Committees in India
Y.K. Gupta, Head, Dept. of Pharmacology; Coordinator, Zonal
Pharmacovigilance Centre, All India Institute of Medical Sciences |
 |
Safety Reporting in India Clinical Research Environment
Kamala Rai, M.D., Research Director, MSD Pharmaceuticals Pvt
Ltd; Medical Director, Merck (India) |
 |
Accelerate Oncology Clinical Development in Asia
Michael Shi, Director and Biomarker Project Leader, Exploratory
Oncology Development, Novartis Oncology |
 |
Are You Ready for an FDA Inspection?
Cherif Benattia, M.D., Vice President, Pharmacovigilance &
Public Health, Vertex Pharmaceuticals |
 |
The Strategic Planning Behind the Clinical Site Allocation
in Emerging Economies: An Industry-Wide View
Fabio Thiers, M.D., M.Sc., Ph.D., Research Associate, MIT Center
for Biomedical Innovation, MIT |
|
|
|
SESSIONS:
|
-
Designing and Planning Trials in India, China and Southeast Asia
-
Managing the Ethical Review Committee Process
-
Safety Reporting and Implementation of Pharmacovigilance Practices at
Indian Sites
-
Effectively Identifying, Selecting and Engaging Clinical Sites
-
Navigating the Regulatory Landscape throughout Asia
-
Strategic and Tactical Considerations when Designing and Conducting
Trials in Asia: Learning from Others
-
Overcoming Logistics, Managing Partners and Ensuring
Compliance
|
 |
|
INTERACTIVE
PANELS:
|
-
Utilizing and Integrating Local Clinical Data from Asia to
Mutually Support Global and Regional Applications
-
Effectively Identifying, Selecting and Engaging Clinical Sites
-
Navigating the Regulatory Landscape throughout Asia
-
Realistic Opportunities and Main Challenges to Conducting
Trials in India, China and Southeast Asia
|
|
|